1. Home
  2. MBWM vs ESPR Comparison

MBWM vs ESPR Comparison

Compare MBWM & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercantile Bank Corporation

MBWM

Mercantile Bank Corporation

HOLD

Current Price

$52.27

Market Cap

881.8M

Sector

Finance

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.12

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBWM
ESPR
Founded
1997
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
881.8M
731.9M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
MBWM
ESPR
Price
$52.27
$3.12
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$55.67
$8.75
AVG Volume (30 Days)
98.8K
7.5M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
3.08%
N/A
EPS Growth
10.95
60.71
EPS
5.47
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$20.28
N/A
Revenue Next Year
$4.67
$12.81
P/E Ratio
$9.35
N/A
Revenue Growth
N/A
21.31
52 Week Low
$42.17
$0.73
52 Week High
$55.77
$4.18

Technical Indicators

Market Signals
Indicator
MBWM
ESPR
Relative Strength Index (RSI) 52.64 71.80
Support Level $47.78 $2.37
Resistance Level $54.90 $3.33
Average True Range (ATR) 1.47 0.14
MACD -0.10 0.09
Stochastic Oscillator 45.39 98.13

Price Performance

Historical Comparison
MBWM
ESPR

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: